Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV Vaccine

Pharmaceutical Investing

Bavarian Nordic (OMX: BAVA) today announced additional positive data from its 421 patient, Phase 2 study investigating the safety and immune effects of its universal RSV vaccine, MVA-BN RSV in an older adult population. As quoted in the press release: “The presence of mucosal IgA in vaccinated subjects is a truly encouraging, demonstrating that our …

As quoted in the press release:

“The presence of mucosal IgA in vaccinated subjects is a truly encouraging, demonstrating that our vaccine is performing as intended. The ability to fight off a severe RSV infection wanes as individuals get older. Observing a booster effect in this elderly population gives us additional confidence that protection against RSV may be possible in this at-risk population using our vaccine. With a mortality rate on par with influenza, the need for an RSV vaccine remains significant,” said Paul Chaplin, President and CEO of Bavarian Nordic.

Click here to read the full press release.

patient phase 2 study us vaccine Pharmaceutical Investing